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Abstract 
Most bacteriophages encode two types of cell wall lytic proteins: endolysins 
(lysins) and virion-associated peptidoglycan hydrolases. Both enzymes have the ability 
to degrade the peptidoglycan of Gram positive bacteria resulting in cell lysis when they 
are applied externally. Bacteriophage lytic proteins have a demonstrated potential in 
treating animal models of infectious diseases. There has also been an increase in the 
study of these lytic proteins for their application in areas such as food safety, pathogen 
detection/diagnosis, surfaces disinfection, vaccine development and nanotechnology. 
This review summarizes the more recent developments, outlines the full potential of 
these proteins to develop new biotechnological tools and discusses the feasibility of 
these proposals.   
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Introduction 
Bacteriophages (phages) are viruses that infect bacteria and thus have co-
evolved with their bacterial hosts, optimizing their propagation within the cell and the 
mechanism of their release from within the cell to the environment. Double-stranded 
DNA phages express  virion-associated peptidoglycan hydrolase (VAPGH) proteins that  
bind to cell surface antigens with high specificity, and disrupt the bacterial cell wall, 
allowing the phage to inject its DNA into the host cell (Fig. 1) (Moak and Molineux, 
2004; Rodríguez-Rubio et al., 2013a). VAPGHs are generally attached to the viral 
particle contacting the bacterial surface in the first step of the infection process. During 
the late stages of infection, phage-encoded endolysins (or lysins) accumulate in the 
bacterial cytoplasm until the assembly of the viral particles is complete. Other 
bacteriophage-encoded proteins, holins, form pores in the cytoplasmic membrane 
permitting the translocation of endolysins across the cytoplasmic membrane which 
degrade the extracellular peptidoglycan (Wang et al., 2000) allowing the cell to 
osmolyse (holin-endolysin lysis system). Some endolysins have been reported to be 
secreted by the general bacterial secretion system and remain inactive, membrane-
anchored until the membrane potential collapses. This process is triggered by a type of 
holins, the pinholins, that accumulate in the membrane and form small pores that 
dissipate the membrane potential (Park et al., 2007). 
Despite the fact that the natural mode of action of endolysins is from within, 
both VAPGHs and endolysins are able to degrade the peptidoglycan of Gram positive 
bacteria when applied exogenously and hence the interest in their use as alternative 
antimicrobials (also named enzybiotics) (Nelson et al., 2012; Rodríguez-Rubio et al., 
2013a). Actually, the increasing incidence of antibiotic resistant bacteria registered in 
the past two decades has renewed the interest in the use of phages (phage therapy) and 
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phage-derived proteins to fight “superbugs” (Sulakvelidze et al., 2001; O’Flaherty et al., 
2009). Phage lytic proteins offer some advantages over phage therapy: a wider host 
spectrum, generally including multiple species from the genus; no potential to transmit 
virulence factors (e.g. antibiotic resistance genes) and lack of resistance development to 
phage lysins (Fischetti, 2008; Rodríguez-Rubio et al., 2013b). In fact, since these lytic 
enzymes encoded by bacteriophages were proposed as new alternatives in the control 
(Nelson et al., 2012; Shen et al., 2012; Rodríguez-Rubio et al., 2013a), and detection of 
pathogenic bacteria (Schmelcher and Loessner, 2014) a remarkable number of papers 
providing information about mode of action, three-dimensional structure, safety, 
specificity, resistance, immunogenicity, synergy and domain shuffling of phage lytic 
proteins have been published (reviewed in Schmelcher et al., 2012). For instance, 
special attention was paid to understand the mode of action and how the presence of 
more than one catalytic domain could be responsible for the low probability of 
resistance development (Schuch et al., 2002; Rodríguez-Rubio et al., 2013b).  
 
Structure and enzymatic activity of endolysins and VAPGHs 
Depending on their origin, the structure of phage lytic proteins can vary. Most 
endolysins from phages infecting Gram-positive bacteria have a modular structure with 
a cell wall binding domain (CBD), usually at the C-terminus and one or two catalytic 
domains, usually at the N-terminus separated by a short linker (Nelson et al., 2012, 
Shen et al., 2012). A novel phage lysin, PlySK1249 encoded by a prophage of 
Streptococcus dysgalactiae subsp. equisimilis SK1249, has recently been reported to 
harbor a central CBD surrounded by an N-terminal catalytic domain and a C-terminal 
catalytic domain (Oechslin et al., 2013). An exception to this modular organization is 
the structurally unique streptococcal PlyC endolysin, composed of two different gene 
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products, PlyCA and PlyCB, with a ratio of eight PlyCB subunits for each PlyCA in its 
active heteromonomer conformation (McGowan et al., 2012). PlyCA subunit harbors 
the enzymatic activity while the eight PlyCB subunits constitute the CBD for the 
complete PlyC protein (Nelson et al., 2006). By contrast, most Gram negative phage 
endolysins have a globular organization with a single catalytic domain (Callewaert et 
al., 2011) and only some reports indicate a modular organization with one or two CBDs 
at the N-terminus and one catalytic domain at the C-terminus (Oliveira et al., 2012), 
which means an inverted molecular orientation compared to endolysins from Gram 
positive phages. 
The Gram negative phage VAPGHs have one catalytic domain, while Gram 
positive phage VAPGHs have two catalytic domains without a recognizable CBD 
(Rodríguez -Rubio et al., 2013a).  
Catalytic domains are responsible for the cleavage of specific bonds within the 
bacterial peptidoglycan. The peptidoglycan backbone is a copolymer formed by an 
alternating sequence of N-acetylmuramic acid (MurNAc) and N-acetylglucosamine 
(GlcNAc) linked by β-1,4 bonds. This sugar backbone can have small variations among 
bacterial species (Schleifer and Kandler, 1972) and is covalently attached to short stem 
peptides, by an amide bond between the MurNAc and the first amino acid in the chain. 
The stem peptide is short and formed by an alternating sequence of L and D form amino 
acids, it is highly conserved in all Gram-negative species but can be highly variable in 
Gram positive species. In many Gram positive species, the third amino acid residue of 
the chain is L-lysine. This amino acid attaches via an interpeptide bridge to a terminal 
D-alanine of another stem peptide. The composition of the interpeptide bridge varies 
between species. In Staphylococcus aureus, for example, the interpeptide bridge is 
formed by 5 glycines (Navarre et al., 1999) and in Streptococcus pyogenes by 2 alanines 
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(Muñoz et al., 1967). Gram negative species and some Gram positive bacteria, such as 
Bacillus and Listeria, have meso-diaminopimelic acid (mDAP) at the third position of 
the peptide instead of L-lysine. This mDAP residue can directly crosslink to the 
terminal D-alanine of an opposing stem peptide without forming an interpeptide bridge. 
Overall, there are six enzymatic activities associated with phage lytic proteins, 
grouped into 3 classes: 
1. Glycosidases. Include the N-acetyl-β-D-glucosaminidase activity, which hydrolyzes 
the β-1,4 bond between the GlcNAc and the MurNAc of the bacterial peptidoglycan; the 
N-acetyl-β-D-muramidase activity which hydrolyzes the β-1,4 bond between the 
MurNAc and the GlcNAc and the lytic transglycosylases. By definition, these latter 
enzymes are not true hydrolase since they do not require water to catalyze the reaction. 
They are very similar to muramidases as they cleave the β-1,4 bond between the 
MurNAc and GlcNAc but involving an intramolecular reaction that results in the 
formation of a 1,6-anhydro ring at the MurNAc residue (Holtje et al., 1975). 
2. Amidases. The N-acetylmuramoyl-L-alanine amidase activity catalyzes the 
hydrolysis of the amide bond between MurNAc and the first amino acid of the stem 
peptide. 
3. Endopeptidases. The endopeptidases hydrolyze the bond between two amino acids 
and include the activities that cleave within the stem peptide of the peptidoglycan, those 
that cleave bonds within the interpeptide bridge and those that cleave between the stem 
peptide and the interpeptide bridge. 
CBD binds to peptidoglycan ligands or secondary cell-wall polymers like 
teichoic acids and neutral polysaccharides (Schmelcher et al., 2012; Ganguly et al., 
2013) found in the cell wall of the host bacterium. They are involved in positioning the 
catalytic domain for efficient cleavage of the peptidoglycan and confer some degree of 
7 
 
specificity to the enzyme (Loessner et al., 2002). Listeria spp. bacteriophages 
endolysins are the best studied regarding the binding ligands and specificity of their 
CBDs (reviewed in Schmelcher et al., 2012). Although CBDs have been shown to be 
necessary for accurate cell wall recognition and subsequent lytic activity in some 
peptidoglycan hydrolases, such as lysostaphin (Baba et al., 1996), ALE-1 (Lu et al., 
2006), Listeria monocytogenes endolysins Ply118 and Ply500 (Loessner et al., 2002) 
and Streptococcus pneumoniae CPL-1 (Pérez-Dorado et al., 2007), there are also 
numerous reports of C-terminally deleted lysin constructs where the N-terminal lytic 
domain maintains its activity or it is even higher in the absence of the CBD (Donovan et 
al., 2006, Cheng et al., 2007, Sass and Bierbaum, 2007, Horgan et al., 2009, Mayer et 
al., 2011). Net charge of catalytic domains influences on protein activity, thus, catalytic 
domains with a positive net charge seem to work independently of the presence of a 
CBD (Low et al., 2011). 
The CBDs of some endolysins are directed towards species- or strain-specific 
cell-wall components that are often essential for viability. For example, amidases PlyG 
and PlyL selectively bind to secondary cell wall polysaccharides of the bacilli cell wall 
(Mo et al., 2012; Ganguly et al., 2013), and amidase Pal contains a choline binding 
module that attaches the enzyme to choline residues present in pneumococcal envelope 
(García et al., 1988). These conserved catalytic and binding targets have been suggested 
to contribute to the lack of bacterial resistance development against phage lytic proteins 
(Fischetti, 2005; Rodriguez-Rubio et al., 2013). 
In contrast to endolysins, VAPGHs do not have a recognizable CBD; however 
the addition of the lysostaphin CBD to the staphylococcal VAPGH HydH5 not only 
enhanced the staphylolytic activity of the protein but also broadened its host range to 
different S. aureus strains and some Staphylococcus epidermidis strains (Rodriguez-
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Rubio et al., 2012). HydH5, as a structural protein, is carried to its substrate in the 
peptidoglycan by the viral particle, which might justify the absence of a CBD. As a 
soluble protein the scenario is quite different and a CBD was necessary for HydH5 to 
properly recognize the host and its targeted bond (Rodriguez-Rubio et al., 2012). 
There are key differences in protein structure between endolysins and VAPGHs 
(e.g. the lack of CBD in VAPGHs); however, they are quite similar at the amino acid 
level suggesting a similar mode of action in their peptidoglycan cleavage mechanisms. 
Both kinds of proteins hydrolyse specific and highly conserved bonds in the 
peptidoglycan structure. 
As mentioned before, phage lytic proteins are highly refractory to resistant 
development due to having co-evolved with the host to target conserved bonds in the 
peptidoglycan (Rodriguez-Rubio et al., 2013). In addition, their modular structure with 
two catalytic domains could also contribute to the lack of resistance observed since two 
lytic domains are expected to be higher refractory to resistance development than one 
domain (Schmelcher et al., 2012; Rodriguez-Rubio et al., 2013b). 
 
State-of-the-art of clinical uses of endolysins 
The use of bacteriophage-encoded peptidoglycan hydrolases as new 
antimicrobials with clinical applications is a promising approach for infectious disease 
therapy (Table 1). Many studies have been carried out in the past decade to apply lysins 
to control pathogens systemically and topically on mucosal surfaces and biofilms 
(Pastagia et al., 2013). The potential of phage lytic enzymes was tested for the first time 
in 2001 to prevent and treat upper respiratory colonization in mice by group A 
streptococci (Nelson et al., 2001). After 2 h of the administration of 500 U of lysin PlyC 
to colonized animals, no remaining bacteria were detected. Subsequent to this work, 
9 
 
multiple studies have demonstrated the efficacy of phage lytic enzymes to control 
different pneumococcal infections such as pneumonia (Loeffler et al., 2001; Jado et al., 
2003; Witzenrath et al., 2009; Doehn et al., 2013), endocarditis (Entenza et al., 2005), 
otitis media (McCullers et al., 2007), meningitis (Grandgirard et al., 2008), bacteremia 
(Loeffler et al., 2003) and mucous membranes colonization (Cheng et al., 2005) using 
murine models of infection. Bactericidal synergism between streptococcal endolysins 
and antibiotics has also been reported in a murine model of pneumococcal bacteremia. 
Combination of subtherapeutic doses of Cpl-1, the pneumococcal Cp-1 bacteriophage 
lysin, with daptomycin significantly increased mice survival (80%) compared with the 
untreated control (0%) and daptomycin (35%) or Cpl-1 monotherapy (0%) after 7 days 
of infection (Vouillamoz et al., 2013).  
The ability of streptococcal lysins to fight infections has also been tested with 
other species, e.g., PlyPy, derived from a prophage infecting S. pyogenes, was recently 
reported to rescue mice from systemic bacteremia caused by that pathogen (Lood et al., 
2014) and repeated injections within 24h of PlySK1249 lysin significantly protected 
mice from Streptococcus agalactiae bacteremia (Oechslin et al., 2013). Noteworthy is 
the novel streptococcal lysin with broad lytic activity PlySs2, derived from a 
Streptococcus suis phage, which has been reported to protect mice from a mixed 
methicillin-resistant S. aureus (MRSA) and S. pyogenes infection (Gilmer et al., 2013). 
 Remarkable results have also been achieved in the treatment of Bacillus 
anthracis infections. This pathogen is highly toxic to humans and thus a potential bio-
warfare or terrorist agent. Two lysins, PlyG and PlyPH protect mice from death after the 
infection with Bacillus cells (Schuch et al., 2002; Yoong et al., 2006). 
Other threatening infections are those caused by MRSA strains against which, 
bacteriophage-encoded lytic proteins have also been proven effective. In 2007, the 
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intraperitoneal administration of the endolysin MV-L from phage phiMR11 protected 
mice against MRSA septic death up to 60 days post infection (Rashel et al., 2007). 
Similar results were obtained with LysGH15 since an intraperitoneal injection of 50 µg 
of the protein administered 1 h after MRSA infection was sufficient to protect mice 
from death (Gu et al., 2011). Recently, an intravenous injection of a pre-formulation 
containing recombinant endolysin SAL-1 prolonged the viability of mice and 
signiﬁcantly reduced MRSA counts in the bloodstream and splenic tissue (Jun et al., 
2013). Another staphylococcal endolysin able to protect mice from a staphylococcal 
bacteremia is endolysin P-27/HP which is able to reduce by 99.9% the presence of S. 
aureus in mice spleens (Gupta and Prasad, 2011). Chimeric proteins have also been 
tested against staphylococcal infections. The chimeric lysin, ClyS, was able to reduce 
by 2-log the MRSA numbers after the administration of one dose in a mouse nasal 
colonization model, to protect animals against death by MRSA in a mouse septicemia 
model and to eradicate skin infections more efficiently than the standard topical 
antibiotic mupirocin (Daniel et al., 2010; Pastagia et al., 2011). Another bacteriophage-
derived chimeric protein, P128, was able to reduce by 2-log an initial MRSA 
colonization of ~10
9
 CFU using 100 μg of the protein twice a day for 3 days in a rat 
nasal colonization model (Paul et al., 2011). Truncated endolysins are also potential 
antistaphylococcal agents as proved by the peptidase domain from endolysin LysK 
(CHAPk) which is effective in the elimination of S. aureus from mice nares as well as a 
decolonization agent for the removal of this pathogen from the surface of mammalian 
skin (Fenton et al., 2010; Fenton et al., 2013). The application of CHAPk as a spray 
removed 99% of S. aureus from porcine skin in 30 min (Fenton et al., 2013). Anti-
staphylococcal endolysins have been combined with antibiotics to treat MRSA 
bacteremia showing superior efficacy to antibiotic therapy alone. This is the case of 
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endolysin CF‐301, also referred to as PlySs2 (Gilmer et al., 2013), which was combined 
with vancomycin or daptomycin increasing mice survival significantly (P<0.0001) 
when compared to antibiotics alone (Schuch et al., 2014). 
Endolysins are largely ineffective against Gram negative bacteria, the primary 
hurdle being the inability of these proteins to cross the bacterial outer membrane. To 
solve this problem several approaches have been reported including the use of 
membrane-disaggregate agents (Callewaert et al., 2011) and fusion of lysins to protein 
domains able to cross the outer membrane (Lukacik et al., 2012). More recently Briers 
and colleagues have developed new endolysin-based antibacterials, named artilysins, 
which combine a phage endolysin with a targeting peptide that transports the endolysin 
through the outer membrane of Gram negative bacteria (Briers et al., 2014a). Thus, Art-
175 is able to pass the outer membrane and kill Pseudomonas aeruginosa, including 
multidrug-resistant strains and persisters, in a rapid and efficient fashion (Briers et al., 
2014b). Despite the fact that a notable number of endolysins against Gram negative 
bacteria have been studied no clinical assays in animals or in humans have been 
reported. 
Overall, bacteriophage-encoded lytic proteins appear to be useful and effective 
as therapeutics against multi-drug resistant Gram positive pathogens. These phage-
encoded lytic enzymes could also be used as disinfectants of medical devices 
(orthopaedic prostheses, indwelling catheters, etc.) to prevent colonization and avoid 
post-surgery infections. However, before extending their use in human therapy it is 
necessary to perform clinical trials to study the effects of these proteins on human 
systems, including a determination of the immune response to these protein agents.  
 
Main biotechnological applications 
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Phage lytic protein applications in different areas are outlined below and summarized in 
Figure 2. 
1. Food safety. The continuous increase in foodborne diseases caused by pathogens 
such as Salmonella, Campylobacter, Escherichia coli and Listeria (EFSA Journal, 
2012) has promoted the research of new technologies to inactivate bacteria in food. An 
essential requirement that should be met by any of these new approaches is that it must 
be safe for humans, animals and the environment while keeping the nutritional value 
and the organoleptic properties of the final product undisturbed. Moreover, 
contaminating bacteria can gain access to food during all stages of production 
(slaughtering, milking, fermentation, processing, storage, packaging) and these new 
technologies have to be applied throughout the complete food chain (“farm to fork”). 
Bacteriophages have been proposed as alternatives to antibiotics in animal health, as 
biopreservatives in food and as tools for detecting pathogenic bacteria throughout the 
food chain (García et al., 2008). The approval of bacteriophages as food processing aid 
in USA [LISTEX
TM
 and SALMONELEX
TM
, Micreos Food Safety 
(http://www.micreos.com); ListShield
TM
, EcoShield
TM
, SalmoFresh
TM
, Intralytix 
(http://www.intralytix.com)] confirms the feasibility of this application. In this context, 
phage lytic proteins have remarkable advantages for food preservation; their narrow 
spectrum of activity allows them to target pathogenic or spoilage bacteria without 
disturbing the commensal microbiota when they are used to reduce colonization in 
livestock. Moreover, they are not active against starter cultures when they are applied as 
preservatives to extend the shelf life of fermented products (García et al., 2010). 
However, their inefficiency against Gram negative bacteria is a disadvantage for the use 
of phage-encoded lytic proteins as biopreservatives against those pathogens.  
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In agriculture, protection against the phytopathogen Erwinia amylovora was 
obtained in transgenic potatoes synthesizing the endolysin from the Escherichia coli 
phage T4 (Düring et al., 1993). Moreover, direct application of the recombinant 
endolysin from E. amylovora phage Ea1h on surfaces of immature pears resulted in a 
delay of necrosis produced by this pathogen (Kim et al., 2004). Other endolysins like 
CMP1 and CN77, from Clavibacter michiganensis phages, have been proposed to 
control this plant pathogen without affecting other bacteria in the soil (Wittmann et al., 
2010). Regarding animal production, transgenic cows expressing endolysins have been 
proposed to reduce mastitis and S. aureus milk contamination (Donovan et al., 2006). In 
fact, chimeric phage lysins were tested in combination with lysostaphin in a mouse 
model of mastitis where they reduced S. aureus counts, gland weights and 
intramammary tumor necrosis factor alpha (Schmelcher et al., 2012). In food 
processing, pathogen biocontrol by endolysins has been approached by addition of these 
proteins as biopreservatives and by expressing endolysin genes in starter or protective 
cultures. The purified staphylococcal endolysin LysH5 killed S. aureus in pasteurized 
milk within 4 h (Obeso et al., 2008) and its activity was enhanced by a synergistic effect 
with nisin (García et al., 2010). Furthermore, the VAPGH-derived fusion protein 
CHAPSH3 (CHAP domain from Hyd5 fused to the SH3 domain from lysostaphin), 
from staphylococcal phage vB_SauS-phiIPLA88, was shown to be active in raw milk 
and retain staphylolytic activity after pasteurization and cold-storage, which could be 
useful in dairy product manufacturing (Rodríguez-Rubio et al., 2013c). In soya milk, 
Listeria monocytogenes contamination was reduced at refrigeration temperature by 
addition of endolysin LysZ5 (Zhang et al., 2012). Other lysins such as the streptococcal 
lysins B30 (Donovan et al., 2006) and Ply700 (Celia et al., 2008) and the chimeric 
streptococcal–staphylococcal constructs λSA2E-Lyso-SH3b and λSA2E-LysK-SH3b 
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(endopeptidase domain from streptococcal LambdaSa2 endolysin fused to lysostaphin 
or LysK SH3b domain, respectively)  have also been reported to be active in milk 
(Schmelcher et al., 2012). In addition, endolysin ctp1l was proposed as an alternative to 
avoid late blowing in cheese production by Clostridium tyrobutyricum (Mayer et al., 
2010). It is tantalizing to consider that recombinant bacteria expressing endolysins 
might exert protective effects in food fermentations (Gaeng et al., 2000). However, the 
listerial phage endolysin Ply511 expressed in an active form in lactic acid bacteria was 
unable to significantly inhibit L. monocytogenes growth (Turner et al., 2007).  The 
staphylolytic endolysin LysH5 that is active in milk (Obeso et al., 2008) was expressed 
and secreted from L. lactis using the signal peptide of bacteriocin lactococcin 972 but 
the protective activity in milk has not yet been assessed (Rodríguez-Rubio et al., 2012). 
Although it is known that endolysins are active in different food matrices, additional 
information is needed as to the effectiveness of these proteins after oral administration 
in humans.    
2. Pathogen detection. Rapid and effective detection of pathogens is very important for 
the proper treatment and prevention of disease. Regarding the use of phage proteins to 
detect pathogens, most of studies have focused on the detection of foodborne bacteria. 
In 2007, Kretzer et al. developed a system to detect and immobilize cells of L. 
monocytogenes on magnetic beads coated with CBDs from different Listeria phages 
endolysins, enabling detection rates of >90% which is superior to the standard plating 
procedure in terms of both sensitivity and time required. Subsequently, Schmelcher et 
al. (2010) used this method to recover Listeria cells from inoculated milk and cheese, 
and were able to differentiate serotypes after incubation with CBDs fused to different 
fluorescent proteins. Tolba et al. (2012) also developed a biosensor for a rapid and 
specific detection of Listeria cells using endolysins CBDs immobilized on a gold screen 
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printed electrode and subsequent electrochemical impedance spectroscopy. The limit of 
detection was 1.1 × 10
4
 and 10
5
 CFU/ml in pure culture of Listeria innocua serovar 6b 
and 2% artificially contaminated milk, respectively (Tolba et al., 2012). Other methods 
based on endolysins have been developed to detect B. anthracis (Fujinami et al., 2007, 
Sainathrao et al., 2009). Using the C-terminal region of γ-phage lysin protein (PlyG), 
Fujinamii et al., (2007) developed a bioprobe to detect B. anthracis with a membrane 
direct blot assay which turned out to be simpler and less expensive than other genetic 
tools such as PCR, or immunological methods using specific antibodies. Later, 
Sainathrao et al. (2009) demonstrated that a 10-amino acids motif from the C-terminal 
region of PlyG coupled with fluorescent Qdot-nanocrystals is sufficient to specifically 
detect B. anthracis. 
3. Surface disinfection. One of the most important challenges in clinical environments 
and in food industry is the presence of bacterial biofilms on medical devices and 
industry surfaces (Otto, 2008; Gutiérrez et al., 2012). Bacteria embedded in biofilms are 
considerably less susceptible to antibiotics and disinfectants than their planktonic 
counterparts, due to both a reduced growth rate and limited access of those compounds 
to bacteria in a biofilm (Davies, 2003). Reduced susceptibility to antibiotics of some 
bacteria within the biofilm which showed a more recalcitrant phenotypic state (persister 
cells) have been also implicated in recurrent infections (Lewis, 2007). Problems 
associated with biofilms could be overcome by using endolysins and VAPGHs and they 
have been tested in both clinical and food production environments. Staphylococcal 
phage endolysins and truncated derivative proteins have been tested against S. aureus 
and S. epidermidis biofilms. The recombinant endolysins of phages phi11 and SAP-2 
were able to remove S. aureus biofilms formed on polystyrene surfaces (Sass and 
Bierbaum, 2007; Son et al., 2010). In addition, bacteriophage K derived peptidase, 
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CHAPk, successfully prevented and removed S. aureus biofilms formed on artificial 
surfaces (Fenton et al., 2013). Furthermore, endolysin LysH5 was almost as effective 
against S. aureus as S. epidermidis biofilms and no resistant cells were observed after 
treatment with this protein (Gutiérrez et al., unpublished). S. suis is an important animal 
pathogen that is also a zoonotic agent infecting humans. A phage endolysin, LysSMP 
led to more than 80% reduction of biofilms formed by these bacteria (Meng et al., 
2011). Moreover, other phage endolysins, Cpl-1 and Cpl-7, were very efficient in 
destroying biofilms formed by S. pneumoniae and the closely related species 
Streptococcus pseudoneumoniae and Streptococcus oralis (Domenech et al., 2011). 
Recently, Shen et al., (2013) demonstrated that endolysin PlyC directly lyses S. 
pyogenes cells within the biofilm matrix due to its ability to diffuse through the 
extracellular material.  
4. Vaccine development. Vaccination, stimulating the immune system to increase the 
adaptive immunity to a pathogen by the administration of antigenic material, represents 
one of the greatest public health triumphs. Viral nanoparticles (VNPs) have been an 
active area of research as delivery platforms for protein and peptide-based vaccines. 
Bacteriophage-derived nanoparticles, however, have attracted much interest since 
foreign peptides or proteins can be displayed on the surface of phages as fusion 
proteins. Thus, phage-displayed peptides or proteins have been shown to be functionally 
and immunologically active, what makes them suitable for vaccine development 
(Hamzeh-Mivehroud et al., 2013). In the search of live vaccine delivery systems, lysins 
can also be used as anchor to display heterologous proteins on the surfaces of bacteria. 
For example, CBDs can be fuse to other proteins (such as antigens) in order to display 
them at the bacterial surface, conserving both their conformation and activity (Loessner 
et al., 2002). Lactic acid bacteria (LAB) have been used to develop surface display 
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systems based on phage endolysins (Hu et al., 2010, Ribelles et al., 2013) in large part 
due to their GRAS status (generally recognized as safe), which makes them more 
readily accepted in medical and food applications than other bacteria. Regarding the 
application of these systems, recently, Ribelles et al. (2013) demonstrated that the 
exogenous addition of the E7 antigen, from human papillomavirus type-16 (HPV-16), 
when anchored on the surface of LAB by the CBD of Lactobacillus casei A2 phage 
endolysin, protected mice against a HPV-16-challenge and the resultant tumors. Over 
60% of the mice remained tumor-free throughout the test period (35 days) after being 
immunized via intranasal vaccination with LAB displaying E7 antigen; the rest of mice 
presented tumors 10-fold smaller than the ones measured in non-treated mice. Thus, 
surface display of endolysins CBDs is an interesting system to further direct therapeutic 
proteins to the surface of otherwise non-genetically modified bacteria in a safe and low-
cost way.  
Endolysins have also been used to produce empty ‘ghost’ bacteria to be 
developed into vaccines. These bacterial ‘ghosts’ are produced by the controlled 
expression of phage PhiX174 lysis gene E. E-mediated lysis of bacteria outcomes in the 
formation of empty bacterial cell envelopes with essentially the same cell surface 
composition as their living counterparts (Eko et al., 1999; Haidinger et al., 2003). These 
ghost bacteria are able to induce a strong immune response and to protect against 
infection. Thus, mucosal immunization with ‘ghost’ cells protects over 93% of mice 
against E. coli O157:H7 and Helicobacter pylori (Mayr et al., 2005; Panthel et al., 
2003). Ghost-bacteria oral vaccines have also been used with promising results to 
prevent the infection of fish with Aeromonas hydrophila and Flavobacterium 
columnare (Tu et al., 2010; Zhu et al., 2012) and protected chicken against Salmonella 
Enteritidis (Peng et al., 2011). However, the development of genetically inactivated 
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bacterial vaccines often requires the use of plasmid encoded antibiotic resistance gene 
markers, whose presence can increase the risk of horizontal spread of those resistance 
genes. In this context, Jawale and Lee (2013) developed an immunogenic Salmonella 
Enteritidis ghost using an antibiotic resistance marker free plasmid carrying the 
bacteriophage PhiX174 lysis system. This S. Enteritidis ghost was evaluated in chickens 
by prime-boost vaccination using a combination of oral and intramuscular routes. After 
a S. Enteritidis challenge, all immunized animals showed fewer gross lesions and 
decreased bacterial recovery from organs in comparison with the non-immunized 
control group (Jawale and Lee, 2013). 
5. Nanotechnology. Among all the fields that enclose the nanotechnology, its relevance 
in the food sector is a relatively recent event compared with its use in medicine and 
pharmaceutics. In fact, many researchers in bionanoscience and bionanotechnology 
were conducted, and phage-based nanomaterials have been described for biomedical 
applications (Farr et al., 2013). Phage lytic enzyme Ply500 was used for surface-based 
applications to prevent contact-based bacterial infections. For biotechnological 
processes, endolysins should be immobilized onto surfaces, with long shelf-lives and 
activity. The immobilization of Ply500 onto FDA approved nanoscale silica particles 
(Ply500-SNP), improved its stability at both 4ºC and 25ºC, and a step forward was 
achieved when incorporating this Ply500-SNP to a poly-hydroxyethyl methacrylate film 
which was able to completely remove listeria cells on contact at 4ºC (Solanki et al., 
2013). This might find application for endolysins as potential anti-bacteria coatings of 
cold storage or food processing equipment. Moreover, starch conjugates with 
endolysins may find further application in antimicrobial packaging systems like 
spraying/coating on food before packaging or incorporation into packaging materials 
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(Solanki et al., 2013). Nanotechnology opens new avenues for the application of 
endolysins and VAPGHs in different sectors to improve human health, and food safety. 
 
Other applications 
Bacteriophage-encoded lytic proteins can also have other biotechnological 
applications different from those mentioned above. Phage lysins can also be useful to 
identify novel targets for antimicrobials development. This is the case of B. anthracis-
specific endolysin PlyG which was used to identify an enzyme involved in the synthesis 
of its receptor and bacterial growth (Schuch et al., 2013). By synthesizing a specific 
inhibitor of this enzyme, named epimerox, authors were able to obtain a potent inhibitor 
of B. anthracis growth in vitro and in vivo in mice challenged with lethal doses of the 
pathogen (Schuch et al., 2013). 
The phage holin–endolysin lysis system can be used in the microbial production 
of bio-based chemicals to disrupt cells and facilitated downstream processing. This 
approach is economically more feasible and easier to control than traditional methods of 
cell disruption (reviewed by Gao et al., 2013). Furthermore, phage endolysins have been 
used for DNA, RNA and protein release from Gram-positive bacteria such as Listeria 
(Loessner et al., 1995) or S. pyogenes (Köller et al., 2008) and for the development of 
auto-inducible or heat-inducible E. coli lysis system to facilitate protein expression 
(Zhang et al., 2009; Carnes et al., 2009). 
Two recent applications of bacteriophage-encoded lytic enzymes is the control 
of bacterial growth in biofermentation and in diagnostic testing. Contamination of 
fermentation cultures by LAB reduces yields of ethanol, weakening the economics of 
biofuel production. Roach et al. (2013) demonstrated that the streptococcal phage 
LambdaSa2 endolysin and several Lactobacillus bacteriophage endolysins were able to 
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lyse lactobacilli, staphylococci or streptococci strains under fermentation conditions. In 
addition, LambdaSa2 endolysin and one of the Lactobacillus bacteriophage endolysins 
were able to reduce both L. fermentum and L. reuteri contaminants in mock 
fermentations of corn fiber hydrolysates (Roach et al., 2013). Another example of the 
control of bacterial growth using phage endolysins was proposed by Subramanyam et 
al. (2013). These authors used a pool of three endolysins to control the overgrowth of 
the normal microbiota in processed sputum samples in order to properly detect 
Mycobacterium tuberculosis. The rate of growth of normal microbiota for the detection 
method using the phage lysin pool was 9.3% compared with untreated samples 
(Subramanyam et al., 2013). Similar results were obtained when antibiotics were used 
to decontaminate sputum samples (Subramanyam et al., 2011); however, antibiotics also 
reduce the growth rate of mycobacteria. In this context, endolysins demonstrated to be 
as effective as antibiotics without inhibiting M. tuberculosis growth (Subramanyam et 
al., 2013). 
 
Perspectives and conclusions 
Endolysins and VAPGHs have repeatedly shown their antimicrobial potential to 
fight against numerous pathogens, being a feasible alternative to antibiotics in the 
treatment of infectious diseases. Results are so promising that new approaches are being 
investigated to exploit this antimicrobial potential in other fields such as food safety, 
surface decontamination and nanotechnology. However, not only their antimicrobial 
activities make these proteins attractive but also the specificity of their CBDs can be 
exploited as powerful tools for bacterial detection and antigen presentation. Considering 
that bacteriophages are the most abundant live entities, phage lytic proteins are 
structurally and functionally diverse which along with current protein engineering tools 
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opens a promising future with broad potential for these proteins. Nevertheless, the 
prospects of phage lytic proteins as biotechnological tools have several hurdles to 
overcome. For instance, in a food safety context, the approval of phage-derived proteins 
as authorized biopreservatives, the production costs and consumer acceptance seem to 
be the primary obstacles. Although no adverse effects were observed after mucosal or 
systemic administration of phage lytic proteins (Fischetti, 2008), further research is 
needed on their cytotoxicity and immunogenicity in order to confirm their safety for 
oral administration as food additives. It is known that endolysins are able to generate an 
antibody response but neutralization of the protein was not observed (Jado et al., 2003). 
Another issue to overcome for the pharmacological or biotechnological use of 
endolysins, especially for disinfection of food industry or healthcare environments, is 
the thermolabile nature of these enzymes. For example, it has been reported that S. 
aureus endolysin LysK, S. pneumoniae endolysins Cpl-1 and Pal and S. pyogenes 
endolysin PlyC lose activity at 42°C, 43.5°C, 50.2°C and 45ºC respectively (Filatova et 
al., 2010; Sanz et al., 1993; Varea et al., 2004; Heselpoth et al., 2012). Another example 
is S. aureus endolysin LysH5 which is active in milk but has no activity after 30 min at 
63ºC (Obeso et al., 2008) conditions used in milk pasteurization. Thus, increase 
thermostability of phage endolysins by protein engineering can be an important 
approach for future applications of these enzymes. Regarding nanotechnological 
applications, phage lytic proteins have a great potential for development of new 
materials because they provide a non-toxic approach to eliminate pathogens through 
bactericidal surfaces in food and healthcare environments. In addition, the very strong 
binding affinity of their CBDs for the bacterial cell wall ligands makes these domains a 
perfect alternative to antibodies, which are more laborious to obtain, for biosensor 
development. 
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The potential of phage lytic proteins is diverse.  There are several companies 
working on phage therapy (Ampliphi, Phage Biotech, Intralytix, Gangagen), who have 
paved the way for phage applications in both human and animal health, and food safety. 
It is a natural progression to expect that the similarly diverse properties and high 
potential of phage lytic proteins as antimicrobials and biotechnological tools will 
encourage the exploitation of these unique proteins. In fact, nowadays Micreos Human 
Health already has on the market several endolysin-based products under the 
GLADSKIN
TM
 brand (www.gladskin.com) for people with acne, eczema and rosacea, 
and ContraFect Corporation (Schuch et al., 2014) is testing, in Phase I clinical trials, 
phage lytic proteins for treatment of life-threatening, drug-resistant infectious diseases.  
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Tables 
Table 1. Potential clinical uses of bacteriophage-encoded peptidoglycan hydrolases 
ENDOLYSIN TREAT OR PREVENT CAUSED BY REFERENCE 
PlyC Upper respiratory colonization  Group A streptococci  Nelson et al., 2001 
Pal Nasopharyngeal colonization and 
bacteraemia 
S. pneumoniae Loeffler et al., 2001, Jado 
et al., 2003 
Cpl-1  Bacteremia, endocarditis, meningitis, 
pneumonia, otitis media 
S. pneumoniae Jado et al., 2003, Loeffler 
et al., 2003, Entenza et al., 
2005, McCullers et al., 
2007,  
Grandgirard et al., 2008; 
Witzenrath et al., 2009,  
Doehn et al., 2013, 
Vouillamoz et al., 2013 
PlyPy Bacteremia S. pyogenes Lood et al., 2014 
PlySK1249 Bacteremia S. agalactiae Oechslin et al., 2013 
PlySs2 (CF-301) Mixed infections and bacteremia MRSA, S. pyogenes Gilmer et al., 2013, Schuch 
et al., 2014 
PlyGBS Vagina and oropharynx colonization Group B streptococci  Cheng et al., 2005 
PlyG Infections B. anthracis Schuch et al., 2002 
PlyPH Infections B. anthracis Yoong et al., 2006 
MV-L  Septic death MRSA Rashel et al., 2007 
LysGH15 Septic death MRSA Gu et al., 2011 
SAL-1  Septic death MRSA Jun et al., 2013 
P-27/HP  Bacteremia  S. aureus Gupta and Prasad, 2011 
ClyS Nasal colonization, skin infections 
and septicemia 
MRSA Daniel et al., 2010; 
Pastagia et al., 2011 
P128 Nasal colonization MRSA Paul et al., 2011 
CHAPk Nasal and skin colonization S. aureus Fenton et al., 2010, 2013 
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Figures 
Figure 1. Mode of action of phage lytic proteins. A) Location of VAPGH protein at the 
phage particle and its role in the infection process. B) Structure of Gram positive 
bacteria cell wall and role of the endolysin protein.  Light grey hexagon: N-
acetylglucosamine (GlcNAc); Dark grey hexagon: N-acetylmuramic acid (MurNAc). 
 
Figure 2. Main biotechnological applications of phage lytic proteins. Modular structure 
of these proteins (EAD= enzymatically active domain, CBD= cell binding domain) is 
indicated. Pathogen detection and vaccines development have been mainly developed 
by using the CBD of lytic proteins, while for food safety, surface disinfection and 
nanotechnology purposes complete proteins were used. LAB: lactic acid bacteria.    
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